Mundipharma (China) Pharmaceutical Co. Ltd
18
0
0
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
50%
9 trials in Phase 3/4
60%
9 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
OTR Tablet 40 mg Fasted-state Bioequivalence Study
Role: lead
OTR Tablet 10 mg Fasted-state Bioequivalence Study
Role: lead
OTR Tablet 40 mg Fed-state Bioequivalence Study
Role: lead
OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study
Role: lead
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
Role: lead
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Role: lead
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
Role: lead
A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain
Role: lead
Buprenorphine Transdermal Patches Pharmacokinetic Study
Role: lead
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
Role: lead
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Role: lead
OxyNorm Capsules in Post-Operative Pain Study
Role: lead
Targin for Non-cancer Pain
Role: lead
Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain
Role: lead
Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment
Role: lead
Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient
Role: lead
NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain
Role: lead
Norspan Transdermal Patches Study in Osteoarthritis Patients
Role: lead
All 18 trials loaded